Chidamide | List of Frontiers open access articles

Original Research

Published on 03 Dec 2021

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

in Hematologic Malignancies

Mengya Zhong
Jinshui Tan
Guangchao Pan
Yuelong Jiang
Hui Zhou
Qian Lai
Qinwei Chen
Liyuan Fan
Manman Deng
Bing Xu

Frontiers in Oncology

doi 10.3389/fonc.2021.780118

6,470 views
8 citations

Original Research

Published on 28 Aug 2024

Predicting the efficiency of chidamide in patients with angioimmunoblastic T-cell lymphoma using machine learning algorithm

in Pharmacology of Anti-Cancer Drugs

Chunlan Zhang
Juan Xu
Mingyu Gu
Yun Tang
Wenjiao Tang
Jie Wang
Qinyu Liu
Yunfan Yang
Xushu Zhong
Caigang Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1435284

2,306 views
1 citation

Original Research

Published on 19 Oct 2020

Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway

in Pharmacology of Anti-Cancer Drugs

Liman Lin
Yimei Que
Pingfan Lu
Huimin Li
Min Xiao
Xiaojian Zhu
Dengju Li

Frontiers in Pharmacology

doi 10.3389/fphar.2020.569651

5,347 views
27 citations

Original Research

Published on 18 Feb 2022

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells

in Breast Cancer

Xinyang Li
Xiang Yuan
Ziming Wang
Jing Li
Zhiwei Liu
Yukun Wang
Limin Wei
Yuanpei Li
Xinshuai Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.819714

6,625 views
7 citations

Original Research

Published on 03 Dec 2019

Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels

in Hematologic Malignancies

He Huang
Yang Wenbing
Aishu Dong
Zhewei He
Rongxing Yao
Wenjian Guo

Frontiers in Oncology

doi 10.3389/fonc.2019.01276

5,945 views
25 citations

Original Research

Published on 04 Feb 2026

HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway

in Cancer Immunity and Immunotherapy

Zhenyang Gu
Yuchen Liu
Yifan Jiao
Hao Wang
Lili Wang
Ning Le
Xiawei Zhang
Qingyang Liu
Yang Xu
Daihong Liu

Frontiers in Immunology

doi 10.3389/fimmu.2026.1752727

436 views

Original Research

Published on 04 Nov 2021

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

in Hematologic Malignancies

Weiping Liu
Donglu Zhao
Ting Liu
Ting Niu
Yongping Song
Wei Xu
Jie Jin
Qingqing Cai
Huiqiang Huang
Zhiming Li

Frontiers in Oncology

doi 10.3389/fonc.2021.750323

10,897 views
23 citations

Clinical Trial

Published on 20 Aug 2024

Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma

in T Cell Biology

Xiangping Zong
Zhen Yang
Jin Zhou
Zhengming Jin
Depei Wu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1430648

4,012 views
11 citations

Perspective

Published on 09 Dec 2021

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports

in Cancer Molecular Targets and Therapeutics

Bin-Ru Wang
Chao-Ling Wan
Song-Bai Liu
Qiao-Cheng Qiu
Tian-Mei Wu
Jun Wang
Yan-Yan Li
Shuai-Shuai Ge
Yan Qiu
Xiang-Dong Shen

Frontiers in Oncology

doi 10.3389/fonc.2021.797941

4,692 views
16 citations

Original Research

Published on 08 Nov 2022

Identification of potential target genes of breast cancer in response to Chidamide treatment

in Cellular Biochemistry

Han Han
Xue Feng
Yarui Guo
Meijia Cheng
Zhengguo Cui
Shanchun Guo
Weiqiang Zhou

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2022.999582

4,463 views
3 citations

Original Research

Published on 04 Apr 2022

LncRNA ENST869 Targeting Nestin Transcriptional Region to Affect the Pharmacological Effects of Chidamide in Breast Cancer Cells

in Pharmacology of Anti-Cancer Drugs

Xiuyan Feng
Han Han
Yarui Guo
Xue Feng
Shanchun Guo
Weiqiang Zhou

Frontiers in Oncology

doi 10.3389/fonc.2022.874343

3,988 views
6 citations

Original Research

Published on 02 Feb 2023

Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study

in Hematology

Xin-Yu Li
Xia-Wei Han
Ke Huang
Ya-Ting Zhang
Hong-Gui Xu
Dun-Hua Zhou
Lu-Hong Xu
Jian-Pei Fang

Frontiers in Medicine

doi 10.3389/fmed.2023.1096529

3,561 views
11 citations

Original Research

Published on 01 Jun 2021

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL

in Hematologic Malignancies

Chong Wei
Shaoxuan Hu
Mingjie Luo
Chong Chen
Wei Wang
Wei Zhang
Daobin Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.682436

5,741 views
12 citations

Case Report

Published on 08 Nov 2021

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review

in Hematologic Malignancies

Chao Chen
Wei Zhang
Daobin Zhou
Yan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2021.757403

3,440 views
10 citations

Case Report

Published on 15 May 2025

Successful treatment of an elderly patient with relapsed/refractory angioimmunoblastic T-cell lymphoma with the PI3Kδ inhibitor linperlisib: a Case Report

in Pharmacology of Anti-Cancer Drugs

Ming-Qiang Chu
Ting-Juan Zhang
Qian Yang
Yuan Feng
Chao Lu
Yong-Hui Ji
Jun Qian
Jing-Dong Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1554501

2,795 views

Original Research

Published on 10 Sep 2020

High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients

in Molecular and Cellular Oncology

Yifeng Sun
Zhao Xu
Jifeng Jiang
Tianhong Xu
Jiadai Xu
Peng Liu

Frontiers in Oncology

doi 10.3389/fonc.2020.563666

5,012 views
17 citations

Articles

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

Predicting the efficiency of chidamide in patients with angioimmunoblastic T-cell lymphoma using machine learning algorithm

Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells

Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels

HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports

Identification of potential target genes of breast cancer in response to Chidamide treatment

LncRNA ENST869 Targeting Nestin Transcriptional Region to Affect the Pharmacological Effects of Chidamide in Breast Cancer Cells

Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review

Successful treatment of an elderly patient with relapsed/refractory angioimmunoblastic T-cell lymphoma with the PI3Kδ inhibitor linperlisib: a Case Report

High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients